Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35

On June 22, 2020 Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, reported that the first patient has been treated in the Company’s first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate developed by Heat Biologics’ Pelican Therapeutics subsidiary (Press release, Heat Biologics, JUN 22, 2020, View Source [SID1234561318]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This first-in-human study is expected to enroll up to 30 patients with advanced solid tumors refractory to standard of care. Eligible patients will be enrolled to receive PTX-35 every two weeks until disease progression. Escalating dose levels of PTX-35 will be explored until optimal immunological dose or maximum tolerated dose is established. The objectives of the study include safety evaluation, determination of the recommended Phase 2 dose as well as exploratory analyses of clinical benefit and immunological effect of PTX-35. This trial is supported by a $15.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Jeff Wolf, CEO of Heat Biologics, commented, "This is an important milestone as we advance our first antibody product candidate into clinical development. I am very pleased with our team’s effort in accelerating the development of PTX-35 as well as the speed of execution to initiate our first-in-human study following FDA clearance of our Investigational New Drug (IND) Application. I believe that PTX-35, our potential first-in-class T-cell co-stimulatory antibody, will offer a differentiated approach to benefit cancer patients."

About PTX-35

PTX-35 is a novel, potential first-in-class antibody T-cell co-stimulator targeting TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells. TNFRSF25 agonism leads to activation of antigen-experienced memory CD8+ T cells, which are instrumental for tumor destruction. Preclinical studies have demonstrated that PTX-35, in combination with antigen-driven immunotherapies, resulted in enhanced anti-tumor properties, including potent proliferation of antigen-specific T cells, production of effector cytokines and augmented effector immune function. A favorable safety profile was demonstrated in preclinical studies, with no deleterious cytokine release in mice, non-human primates or in vitro human immune cells.

A $15.2 million grant has been awarded by Cancer Prevention and Research Institute of Texas (CPRIT) to support the pre-clinical development, manufacturing and Phase 1 clinical development for PTX-35.

Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020

On June 22, 2020 Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported its broad viral vector expertise and their potential to transform the fight against cancer at the AACR (Free AACR Whitepaper) 2020 Virtual Annual Meeting II (Press release, Transgene, JUN 22, 2020, View Source [SID1234561334]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

myvac
Transgene presents data demonstrating that the prediction algorithm used to customize TG4050 for each patient is accurate at identifying immunogenic cancer mutations even among a large set of candidate tumor mutations.
The poster is entitled:
"Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine" (#4566)

Because only 1 to 5% of tumor mutations are immunogenic, they can be particularly difficult to identify. To demonstrate the accuracy of the prediction algorithm, Transgene and NEC analyzed 6 tumor samples from patients with non-small cell lung cancer eligible for tumor resection. NSCLC are highly mutated tumors that thus generated a massive amount of data that proved compatible with the machine learning approach.
More than 86% of top ranked peptides identified were immunogenic. The NEC/Transgene prediction system was also able to identify immunogenic peptides that were missed by netMHCpan 4.0, the industry standard predictor.
These results demonstrate that the specificity of our approach outperforms the industry standard and are expected to translate in enhanced activity in patients.
Two PoC Phase 1 clinical trials evaluating TG4050, the first therapeutic vaccine leveraging this algorithm, are ongoing in the USA and in Europe.
The poster can be downloaded on the AACR (Free AACR Whitepaper) website and here.

___________________

Invir.IOTM

Transgene is presenting preclinical data on two oncolytic viruses derived from the Invir.IO platform, the clinical-stage BT-001 and the new candidate TG6010.

BT-001
Transgene and BioInvent are presenting a poster that supports the clinical development of BT-001, an anti-CTLA4 antibody-encoding oncolytic virus, against solid tumors:
"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment." (#5602)

Cure rates exceeding 70% were seen in multiple mouse models, demonstrating the powerful therapeutic effect of BT-001 when used as a single agent, providing a solid basis for BT-001’s upcoming clinical development, with a Phase 1 clinical trial expected to start before the end of 2020.
The anti-CTLA-4 antibody and GM-CSF accumulate in tumors with low systemic exposure. Concentrations of the anti-CTLA-4 antibody in the tumor after intratumoral injection of BT-001 is more than 10-fold higher than after intraperitoneal injection of 3 mg/kg of the recombinant antibody in a xenograft tumor model.
When tumor cells were re-implanted in mice that had been cured after a first BT-001 treatment, a strong tumor-specific response and long-lasting immune memory were developed by these mice.
BT-001, even at sub-optimal dose, reinforced the therapeutic activity of anti-PD-1 treatment – opening up potential combinations for powerful dual checkpoint blockade treatment regimens
The poster can be downloaded on the AACR (Free AACR Whitepaper) website and here.

More details are available in the press release distributed simultaneously and available on www.transgene.fr.

TG6010
Transgene is also presenting preclinical data obtained with TG6010, an Invir.IO based oncolytic virus encoding human cytidine deaminase (hCD) in a poster entitled:
"Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects" (#4576)

In addition to the intrinsic properties of the Invir.IO viral vector (superior oncolysis, immunogenic cell death, stimulation of innate and adaptive immune responses), TG6010 directly expresses hCD in the tumor micro-environment.
hCD is an enzyme that converts cytidine into uridine. Cytidine being one of the 4 nucleotides that compose DNA, it is absolutely necessary to enable cell replication and tumor progression.
By expressing hCD in the tumor, TG6010 will indirectly deprive cancer cells from the material they need to replicate, leading to DNA instability and ultimately cell death (apoptosis).
The preclinical data presented at AACR (Free AACR Whitepaper) also show that the activity of TG6010 is associated with a significant decrease of available cytidine in the plasma, which resulted in a distant antitumor effect.
Additional experiments are being conducted to further assess the potential of TG6010 as a single agent and in combination with other treatments that target tumor cells DNA, and DNA repair mechanisms.

Minerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Technology

On June 22, 2020 Minerva Biotechnologies (Minerva) reported that it has licensed from Memorial Sloan Kettering Cancer Center (MSK) "1XX" technology for use with Minerva’s proprietary anti-MUC1* antibodies to increase CAR T cell persistence in patients (Press release, Minerva Biotechnologies, JUN 22, 2020, View Source [SID1234561350]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This promises to be a great step forward for CAR T cell treatment of solid tumors," said Minerva CEO Dr. Cynthia Bamdad. "We are combining Minerva’s demonstrated cancer-specific antibodies with MSK’s innovative T cell signaling technology that sustains CAR T cell function and persistence."

Minerva is currently in a first-in-human clinical trial for metastatic breast cancers with a CAR T (huMNC2-CAR44) targeting a cleaved form of MUC1 called MUC1* (NCT04020575). MUC1* is the growth factor receptor form of MUC1 that is aberrantly expressed on over 75% of all solid tumors and on over 90% of breast cancers.

CAR T cell persistence, which is the amount of time that infused CAR T cells have the potential to kill tumor cells, is a recognized problem in the revolutionary field of cancer immunotherapy. Since over-activation drives CAR T cell exhaustion, calibrating their activation potential through 1XX mutations in their signaling domain staves off expression of exhaustion molecules that turn CAR T cells off. With this agreement, Minerva will gain non-exclusive access to two of MSK’s innovative CAR T technologies, including the 1XX CAR T cell signaling construct, whose activation potential more closely resembles that of naturally occurring T cells. Minerva expects its next-generation anti-MUC1* CAR T cell therapies to have enhanced therapeutic profiles due to their extended persistence.

Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering at MSK and inventor of the 1XX technology said, "We are excited by the prospect of targeting MUC1* with MSK’s 1XX CAR technology."

Aethlon Medical Presents Hemopurifier® Data at the American Association for Cancer Research 2020 Annual Meeting

On June 22, 2020 Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, reported positive ex vivo data demonstrating the ability of a laboratory version of the Company’s Hemopurifier to capture tumor-derived exosomes in several forms of cancer (Press release, Aethlon Medical, JUN 22, 2020, View Source [SID1234561366]). The data were presented in e-poster format by Dr. Annette Marleau, the Company’s Senior Director of Research, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, on June 22, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Exosomes are subcellular particles that are shed from both normal and malignant cells and have been shown to mediate multiple mechanisms of tumor growth and spread. The e-poster, titled, "Targeting Tumor-Derived Exosomes using a Lectin Affinity Hemofiltration Device", highlights data from ex vivo studies which demonstrate that a laboratory version of the Hemopurifier effectively captures and removes substantial quantities of exosomes from fluid samples that are circulated through the device. The data show that the Hemopurifier can clear exosomes that originate from plasma from patients with diverse cancers, including head and neck cancer, melanoma, ovarian cancer, esophageal cancer and breast cancer. The e-poster is available online at View Source!/9045/presentation/7490.

"Despite abundant research on tumor-derived exosomes and their role in cancer growth and immunosuppression, a clinical strategy for influencing exosomes in oncology has been unavailable," said Timothy C. Rodell, M.D., Chief Executive Officer of Aethlon. "The ability to effectively target and capture exosomes that exhibit signatures of malignancy and immunosuppression offers a potentially powerful therapeutic strategy for cancer. By reducing the presence of tumor-derived exosomes in the circulation of cancer patients, we believe the Hemopurifier may have the potential to improve the benefits of existing cancer treatment regimens and emerging immuno-oncology drugs. Our recently announced Early Feasibility Study in patients with head and neck cancer being treated with pembrolizumab (KeytrudaÒ) may provide human clinical data to complement these in vitro studies."

Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China

On June 22, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, reported that it has entered into an agreement with Betta Pharmaceuticals (SZ300558), a top Chinese pharmaceutical company focusing on the development of innovative oncology therapies, for an exclusive collaboration and license agreement for the development and commercialization of balstilimab and zalifrelimab in Greater China, including Mainland China, Hong Kong, Macau and Taiwan (Press release, Agenus, JUN 22, 2020, View Source [SID1234561275]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Agenus will receive $35 million, which includes $15 million in upfront cash and a $20 million equity investment. The agreement also includes $100 million in potential milestones plus royalties on net sales. Betta receives exclusive rights for the development and commercialization of balstilimab and zalifrelimab to either as monotherapies or combination therapies, excluding intravesical delivery in greater China.

Agenus’ balstilimab (anti-PD-1) is advancing in trials planned for BLA filing this year as a monotherapy and in combination with zalifrelimab (anti-CTLA-4) for the treatment of refractory or metastatic cervical cancer. Agenus has recently reported positive results suggesting robust and durable responses of balstilimab and zalifrelimab in patients with relapsed or refractory metastatic cervical cancer. The US FDA recently granted Fast Track designation for balstilimab alone and in combination with zalifrelimab in this indication.

"Betta has a strong track record of advancing innovative products in China and a growing portfolio of complementary oncology therapies," said Garo Armen, Chairman and Chief Executive Officer of Agenus. "Betta is an ideal partner to enable us to address significant patient needs in China while also advancing global development of balstilimab and zalifrelimab."

"We are delighted to enter this collaboration with Agenus, a leader in the immuno-oncology field, as the first step in a long-term strategic partnership," said Lieming Ding, Chairman and Chief Executive Officer of Betta Pharmaceuticals. " Based on the compelling clinical data reported to date, we believe Agenus’ balstilimab and zalifrelimab hold great promise for Chinese patients with cervical cancer, with the potential to further expand in additional tumor types through synergistic combinations with Betta’s existing pipeline programs."

The equity purchase component of the transaction is subject to China regulatory approval and other customary closing conditions.